Abstract:Acute myeloid leukemia (AML) is an aggressive haematological cancer characterized phenotypically by the rapid clonal growth of myeloid cells and an accumulation of immature blasts. Although major progress has been made in identifying different genetic and molecular AML subgroups, treatment and long-term patient outcomes have not changed significantly over the past four decades. Recently, venetoclax (ABT-199), a selective BCL-2 inhibitor, has been approved for the treatment of older patients with AML. However, drug resistance and disease progression on venetoclax as well as the inherent resistance of leukemic stem cells (LSCs) to therapy pose significant clinical challenges. One candidate target for improved therapies is AXL, a member of the TYRO3/AXL/MER (TAM) family of receptor tyrosine kinases that is elevated in AML cells and LSCs, and associated with poor prognosis in AML. To test whether targeting of AXL is a feasible treatment strategy for AML, in particular to eradicate LSCs, we developed a potent and selective AXL inhibitor. We show that AXL inhibition targets AML cells with high AXL expression and synergizes with venetoclax decreasing the viability of primitive AML patient cells and reducing their clonal short- and long-term colony assay outputs compared to single or control treatments. Moreover, a combination of AXL inhibition and venetoclax treatment was able to target LSCs and AML blasts in two different preclinical patient-derived xenotransplantation (PDX) models. Single-cell RNA-sequencing and functional validation studies revealed that AXL inhibition perturbs oxidative metabolism and differentially targets signaling pathways to synergize with venetoclax in leukemic cell killing. Importantly, the combination of AXL inhibition plus venetoclax was not toxic to normal BM cells from healthy donors. Hence, our findings identify a promising, improved and specific treatment strategy for AML. Acute myeloid leukemia (AML) is an aggressive haematological cancer characterized phenotypically by the rapid clonal growth of myeloid cells and an accumulation of immature blasts. Although major progress has been made in identifying different genetic and molecular AML subgroups, treatment and long-term patient outcomes have not changed significantly over the past four decades. Recently, venetoclax (ABT-199), a selective BCL-2 inhibitor, has been approved for the treatment of older patients with AML. However, drug resistance and disease progression on venetoclax as well as the inherent resistance of leukemic stem cells (LSCs) to therapy pose significant clinical challenges. One candidate target for improved therapies is AXL, a member of the TYRO3/AXL/MER (TAM) family of receptor tyrosine kinases that is elevated in AML cells and LSCs, and associated with poor prognosis in AML. To test whether targeting of AXL is a feasible treatment strategy for AML, in particular to eradicate LSCs, we developed a potent and selective AXL inhibitor. We show that AXL inhibition targets AML cells with high AXL expression and synergizes with venetoclax decreasing the viability of primitive AML patient cells and reducing their clonal short- and long-term colony assay outputs compared to single or control treatments. Moreover, a combination of AXL inhibition and venetoclax treatment was able to target LSCs and AML blasts in two different preclinical patient-derived xenotransplantation (PDX) models. Single-cell RNA-sequencing and functional validation studies revealed that AXL inhibition perturbs oxidative metabolism and differentially targets signaling pathways to synergize with venetoclax in leukemic cell killing. Importantly, the combination of AXL inhibition plus venetoclax was not toxic to normal BM cells from healthy donors. Hence, our findings identify a promising, improved and specific treatment strategy for AML.

A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis

Abivertinib Synergistically Strengthens the Anti‐leukemia Activity of Venetoclax in Acute Myeloid Leukemia in a BTK‐dependent Manner

Venetoclax Plus Cytarabine and Azacitidine in Relapsed/Refractory AML: an Open-Label, Single-arm, Phase 2 Study.

Venetoclax Plus Daunorubicin and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia Patients: A Propensity Score-Matched Analysis

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis

Abstract 3785: ME-344, a Novel Isoflavone Mitochondrial Inhibitor, in Combination with Venetoclax Constitutes a New Metabolism-Targeted Approach to Overcome Resistance to Bcl-2 Inhibition and Standard of Care Treatment in AML

Efficacy and Safety of Venetoclax in Combination with Cytarabine and Azacitidine (VAA) in Relapsed/refractory Acute Myeloid Leukemia: an Open-Label, Single-Arm, Phase II Study.

Venetoclax Plus “3+7” Chemotherapy As the First-Line Therapy for Adult Patients with Acute Myeloid Leukemia

3125 – COMBINING VENETOCLAX TREATMENT WITH AXL KINASE INHIBITION TARGETS CANCER STEM AND PROGENITOR CELLS IN ACUTE MYELOID LEUKEMIA

Enhancing the antileukemic activity of venetoclax against leukemia stem cells by targeting oxidative phosphorylation through dual inhibition of PI3K and HDAC.

Abstract 2463: Enhancing the Antileukemic Activity of Venetoclax Against Leukemia Stem Cells by Targeting Oxidative Phosphorylation Through Dual Inhibition of PI3K and HDAC

Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy

Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Voruciclib, An Oral, Selective Cdk9 Inhibitor, Enhances Cell Death Induced By The Bcl-2 Selective Inhibitor Venetoclax In Acute Myeloid Leukemia

Abstract 7218: Venetoclax triggers apoptosis and augments the effectiveness of doxorubicin against acute myeloid leukemia cells

Combinatorial inhibition of focal adhesion kinase and BCL-2 enhances anti-leukemia activity of venetoclax in acute myeloid leukemia.

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance

Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia

Effect and Mechanism of NL-101 Combined with Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia